J&J Hit With $70 Million Risperdal Verdict Over Male Breasts

Updated on
  • Award is largest in Philadelphia litigation over side effect
  • Drugmaker says award to Tennessee teen is ‘clearly excessive’

A $70 million verdict won by a Tennessee teenager who blamed Johnson & Johnson’s Risperdal drug for causing him to grow female breasts dwarfs awards to other users of the antipsychotic medication who suffered the same side effect.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.